EGb761

Phase 3Small molecule

Ipsen

EGb761 is one of 42 small molecule programs targeting Cognitive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive DisorderActive, not recruiting

StrokeActive, not recruiting

Cognitive DisorderPreclinical

Active, not recruiting

StrokePhase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

EGb761

Ipsen

Phase 3

1 2

Folvite

Eli Lilly

Preclinical

1 3

Proamatine

Repatha

Botox

RRevance Therapeutics, Inc.

Preclinical

2 6

Zantac 150

CChattem

Preclinical

1 7

Haldol

DDePuy Orthopaedics

Preclinical

1 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cognitive Disorder1 trial

EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

Completed· Ipsen logo

Ipsen··NCT02321475·54 enrolled

Cognitive Functions1 trial

Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions

Completed· Ipsen logo

Ipsen·Phase 2·NCT00814346·49 enrolled

Stroke1 trial

A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

Completed· Ipsen logo

Ipsen·Phase 3·NCT00276380·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for EGb761. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EGb761 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EGb761. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ipsen

EGb761

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cognitive Disorder1 trial

Cognitive Functions1 trial

Stroke1 trial

References

Drug Info

Quick Facts

Related News